Navigation Links
Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
Date:11/4/2010

CAMBRIDGE, Mass., Nov. 4, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented positive new data from a Phase III clinical trial (study 039) designed to evaluate the efficacy of VPRIV® (velaglucerase alfa for injection) compared with imiglucerase in patients with type 1 Gaucher disease at the 2010 Annual American Society of Human Genetics (ASHG) in Washington, D.C. The study met its primary endpoint and adds to the growing body of clinical evidence which supports the use of VPRIV in patients who have transitioned from imiglucerase or who are treatment-naive. 

In the 039 (head-to-head) study, adult and pediatric patients with type 1 Gaucher disease were included in a 9-month, global, randomized, double-blind, non-inferiority study comparing VPRIV with imiglucerase in treatment-naive patients aged >/= 2 years, with anemia and either thrombocytopenia or organomegaly. Patients were randomized in a 1:1 ratio to receive either VPRIV or imiglucerase at a dose of 60U/kg via continuous infusion over one hour every other week for 39 weeks (total of 20 infusions per patient). 35 patients in 9 countries were randomized and 34 received the study drug (intent-to-treat [ITT] population was 17 in both the VPRIV and imiglucerase groups). The per-protocol (PP) analysis included 15 patients in each group. Baseline clinical characteristics were generally similar between the 2 groups, although hemoglobin concentrations appeared slightly higher in the VPRIV group.

After 9 months of treatment, hemoglobin concentration improved in both groups. The estimated mean treatment difference for hemoglobin concentration from baseline between patients treated with VPRIV and imiglucerase was 0.14 and 0.16 g/dL in the ITT and PP populations, respectively, with a lower bound of the 97.5% one-sided confidence inte
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... -- Thousands of people will peacefully demonstrate their frustration ... epidemic at dozens of rallies across the country today. ... the United States has experienced skyrocketing rates ... heroin, yet the President has never once spoken publicly ... to President Obama , rally organizers compared his failure ...
(Date:8/31/2015)... 2015 With increasing clinical applications, the ... rise in active partnerships. The primary reason for ... quantitate CD4 cell markers in human immunodeficiency virus ... New analysis from Frost ... Market ( http://www.frost.com/nf0e ), finds the market earned ...
(Date:8/31/2015)... Aug. 31, 2015 The Wolf Administration today ... Pennsylvania State Police and local ... naloxone. Heroin and opioid overdose are the ... , killing more individuals than those involved in ... died from a drug overdose. " ...
Breaking Medicine Technology:Obama Administration's Neglect of Opioid Crisis Prompts Rallies in Many States 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3
(Date:8/31/2015)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... by Movestrong, has launched a new weight management program that is unique to ... highly recommended programs in Oakland and Macomb County. , WEmovestrong’s weight management ...
(Date:8/31/2015)... Ohio (PRWEB) , ... August 31, 2015 , ... ... Michael as Vice President, Marketing and Corporate Communications. In this capacity, Michael will ... , CareSource is an industry leader in consumer-focused programs that have contributed to ...
(Date:8/31/2015)... ... ... The Bay Pines VA Healthcare System (VAHCS) remains focused on ... doctors and nurses and expanding existing facilities and services. Spine surgery will soon ... Jabre was selected to lead and grow the Bay Pines VAHCS’s new spine surgery ...
(Date:8/31/2015)... ... , ... Neuropsychiatric Disease and Treatment has published ... laser phototherapy ”. , As corresponding author Dr Theodore Henderson says “These findings ... mostly palliative treatments only - and now we have shown real clinical and ...
(Date:8/31/2015)... Plains, NJ (PRWEB) , ... August 31, 2015 , ... ... high quality, patient-oriented dental care. From the moment a patient arrives at the ... and Steven Tuckman will work with each and every patient to create a complete ...
Breaking Medicine News(10 mins):Health News:CareSource Names Vice President, Marketing and Corporate Communications 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 3Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Dentists Presents, Clifton Dental Associates! 2
... classic engineering technique may improve decisions about building and ... lower public health costs and healthier children. The ... vaccines to ensure protection from deadly diseases, such as ... production. The stockpiles must be replenished as the vaccines ...
... the hand or arm do not need to be ... comparing regular relocation with relocation on clinical indication, published ... found that rates of complications were the same for ... worked with a team of researchers to carry out ...
... the treatment of depression and the management of physical pain. ... audio engineering the project is looking in more detail than ... project, at Glasgow Caledonian University is supported by the Engineering ... could lead to advances in the use of music to ...
... , THURSDAY, Sept. 9 (HealthDay News) -- In 2000, the ... and vegetables people should eat, but a decade later the ... thresholds, health officials said Thursday. In fact, according to ... 67.5 percent of adults ate fruit less than two times ...
... More than 7,000 psychiatrists, neurologists, psychologists and neuroscience ... 23rd Congress of the European College of Neuropsychopharmacology (ECNP) from ... ECNP Congress is the largest scientific meeting on mental health ... presented by more than 150 distinguished speakers from 20 ...
... Title: The Prospects for Personalized Medicine , Author: ... a working draft of the human genome, major changes ... research, and policy. , Title: Personalized Medicine,s Ragged Edge, ... has a built-in positive spin. But little attention has ...
Cached Medicine News:Health News:Sizing up stockpiles of children's vaccines 2Health News:Sizing up stockpiles of children's vaccines 3Health News:Music on prescription could help treat emotional and physical pain 2Health News:Most Americans Still Not Eating Enough Fruits, Veggies 2Health News:Most Americans Still Not Eating Enough Fruits, Veggies 3Health News:23rd ECNP Congress: Europe's largest scientific meeting on mental health 2Health News:The Hastings Center Report table of contents for September-October 2010 2Health News:The Hastings Center Report table of contents for September-October 2010 3
... a high performance temperature controlled shaker which ... speed and incubation time are fully programmable ... are displayed on the LCD in real ... the microplates provide uniform incubation with less ...
... The iEMS Incubator/Shaker HT ... Thus, the iEMS Incubator/Shaker HT ... as DNA hybridization and primer ... is available as a one-cabinet ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Form: Cream-colored powder Moisture: 10% Ash: 6.5% Gel Strength (1.5%): 550 950 gm/cm 2 Gel pH (1.5%): 6.0 7.5 Gel Point (1.5%): 34 38C Melting Point (1.5%): 84 88C Application: Bacterial ...
Medicine Products: